SARS-CoV-2 Inhibitor Compounds for Rapid Antiviral Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective treatment for severe acute respiratory syndrome caused by coronaviruses such as SARS-CoV-2, which poses a significant threat to human health with high case-fatality rates and rapid evolution.
Innovation Solution
Development of compounds of formula (I) and their pharmaceutically acceptable salts, which inhibit SARS-CoV-2, including various substituents and functional groups, for use in pharmaceutical compositions to treat severe acute respiratory syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment exists for SARS-CoV-2, then the disease can spread freely with high case-fatality rates, but developing new treatments takes time and resources
Solution Approach 1:
The patent applies preliminary action by designing and synthesizing a series of compound candidates before clinical need arises, establishing a pipeline of potential treatments that can be rapidly deployed when needed. The systematic exploration of chemical spaces and pre-characterization of compound properties enables faster transition from discovery to clinical application.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular structures, substituents, and chemical properties of compound candidates to optimize for SARS-CoV-2 inhibition. By adjusting parameters such as molecular weight, functional groups, and chemical moieties, the invention identifies leads with enhanced efficacy and potential therapeutic window.
2Reliability
If comprehensive compound screening is performed, then treatment efficacy can be optimized, but the complexity and cost of development increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into manageable phases: initial compound generation, in silico screening, in vitro validation, and in vivo testing. This modular approach allows systematic evaluation of compound classes while controlling development complexity through structured milestones and criteria.
Solution Approach 2:
The patent employs universality by designing compound frameworks that can address multiple aspects of viral infection through a single molecular platform. The modular chemical structures enable exploration of diverse mechanisms of action (direct viral inhibition, immune modulation, etc.) within a unified development strategy, reducing overall program complexity.
Data Source
AI summary
Inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.